-+ 0.00%
-+ 0.00%
-+ 0.00%

Editas publishes corporate presentation on in vivo gene editing, LDL-C lowering candidate EDIT-401

PUBT·04/17/2026 13:30:51
Listen to the news
Editas publishes corporate presentation on in vivo gene editing, LDL-C lowering candidate EDIT-401
  • Editas highlighted lead in vivo gene-editing program EDIT-401 as a potential one-time treatment for hyperlipidemia, targeting LDLR upregulation via edits in non-coding regulatory regions.
  • Preclinical data showed >90% mean LDL-C reduction in non-human primates.
  • Program timeline targets IND/CTA submission by mid-2026.
  • Development plan targets early human proof-of-concept data by end of 2026.
  • Editas expects to complete enrollment in dose-finding portion in 2027, with topline results also slated for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.